男友太凶猛1v1高h,大地资源在线资源免费观看 ,人妻少妇精品视频二区,极度sm残忍bdsm变态

• Search
• HOME
• CHINA
• WORLD
• BUSINESS
• LIFESTYLE
• CULTURE
• TRAVEL
• VIDEO
• SPORTS
• OPINION
• REGIONAL
• FORUM
• NEWSPAPER
• MOBILE

Global EditionASIA 中文雙語Fran?ais

1. Home
2. World
/ Europe

CureVac fails in COVID-19 vaccine trial with 47% efficacy

By Ouyang Xueyan | chinadaily.com.cn | Updated: 2021-06-18 00:04

Share

Share - WeChat

CLOSE

German biotech CureVac's COVID-19 vaccine has come out of a late-stage trial with 47 percent efficacy but the health ministry has said this will not impact the country's vaccination rollout.

Photos

Statistics as a witness: China-Kazakhstan ties in focus

G7 summit to focus on global economy, energy security

When the light returns

Labubu fever sweeps Australia

Italy, Portugal join tourism protest

West Bank life paralyzed as Israeli closure enters 3rd day

Most Viewed in 24 Hours

World in Focus

When the light returns

Across Asia +

As temperatures rise, poisonous snakes move to high-altitude valleys in Nepal

Indonesia's trade surplus drops sharply in April

Special Coverage +

Live: Iran launches fresh missile attack on Israel

My China Album

Friends Afar +

Ballet maestro's fond China memories

Ties That Bind +

Vital pass to boost China-Pakistan trade

English

中文

Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.

License for publishing multimedia online 0108263

Registration Number: 130349

About China Daily

Advertise on Site

Contact Us

Job Offer

Expat Employment

FOLLOW US